New pill may extend remission for aggressive neuroendocrine cancer patients

NCT ID NCT06926634

First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 26 times

Summary

This study tests whether the drug zanzalintinib, taken as a maintenance therapy after initial chemotherapy, can delay cancer progression in people with high-grade neuroendocrine neoplasms (aggressive tumors). About 32 participants will receive the drug and be monitored for how long their cancer stays stable. The goal is to see if this approach improves progression-free survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE NEUROENDOCRINE NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic - Rochester

    NOT_YET_RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-••••

    Contact

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.